BioSpace News Archive

Cutera, Inc. (Nasdaq: CUTR ) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the second quarter after the market close on Thursday, August 4, 2022.

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), today announced that Chief Scientific Officer and Co-Founder, Dr Julian Kenyon, MD, MB, ChB, reflects on the unique anti-cancer effects of PRP discovered as a result of the significant and diligent research invested by the Company and its joint research team over the past decade.

Therapeutic Solutions International reported the successful generation of gene-edited and/or gene-modified regenerative cells possessing mixtures of properties between mesenchymal stem cells and tolerance inducing immune cells.

Denovo Biopharma LLC (“Denovo”), a pioneer in applying precision medicine to the development of innovative therapies, today announced dosing of the first patient in its biomarker-guided global Phase 2b clinical trial (the “ENLIGHTEN” study) to assess the safety and efficacy of DB104 (liafensine) in patients with treatment resistant depression (TRD).

GT Molecular, a company providing ultrasensitive PCR assays for wastewater-based epidemiology, cancer and pathogen panels has implemented a highly sensitive, wastewater-based test for hMPXV.

Checkpoint Surgical announced today the launch of the Checkpoint Edge™ Nerve Cutting Kit, extending the breadth of the company’s intraoperative nerve care portfolio.

UBC, a biopharmaceutical leader providing integrated clinical, safety, and commercialization services, announced that it has acquired Examoto, LLC, a Risk Evaluation and Mitigation Strategy company.

Diagnostic Robotics, a leading provider of Artificial Intelligence & Care Management solutions for Healthcare plans and providers, today announced the closing of a $45M Series B funding round led by StageOne investors, with participation from Mayo Clinic, thus becoming a Mayo Clinic Platform portfolio company.

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, today announced new efficacy and safety findings from the unblinded period of the HIV Prevention Trials Network (HPTN) 084 trial evaluating cabotegravir long-acting (LA) for pre-exposure prophylaxis (PrEP) in women in sub-Saharan Africa.

Stroke patients with COVID-19 are facing worse outcomes and are often younger and healthier, according to research presented at the Society of NeuroInterventional Surgery’s 19th Annual Meeting.